On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

New test will run on Abbott's Alinity® i laboratory instrument, complementing Abbott's rapid i-STAT TBI Plasma test, cleared by the FDA in 2021 Given the significant number of Alinity i instruments in ...

Two years after Abbott landed FDA clearance for a hand-held blood test that could detect signs of mild traumatic brain injuries (TBIs) in the span of about 15 minutes, the concussion-spotting test is ...

Abbott's Alinity i TBI lab test offers a new reliable result in 18 minutes to help clinicians quickly assess concussion and triage patients. For those with negative results, it rules out the need for ...

Abbott Laboratories (NYSE:ABT) posted higher sales of $10.24 billion in the fourth quarter, despite continued soft demand for the company’s Covid-19 testing equipment, beating the consensus of $10.18 ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

https://www.thehindubusinessline.com/companies/abbott-launches-lab-based-test-to-evaluate-concussions/article69736132.ece Copy Healthcare company Abbott has launched ...

Abbott (NYSE: ABT) has announced the global launch of the ACCELERATOR® a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling ...

Abbott Laboratories ABT CEO Robert Ford, while speaking at the HLTH conference in Las Vegas, outlined the company's strategic move into the consumer wearables market. While Abbott has historically ...

(Reuters) - Abbott Laboratories Chief Executive Officer Robert Ford said on Tuesday demand for COVID-19 testing has surged globally and that sales of its tests should stay strong in the near term. "We ...

Abbott Laboratories (NYSE:ABT) reports Q3 2023 sales of $10.1 billion, a decrease of 2.6% due to anticipated decline in COVID-19 testing-related sales. Company's GAAP diluted EPS stands at $0.82, with ...